Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin

被引:16
作者
Lertkiatmongkol, Panida [1 ,2 ,3 ]
Assawamakin, Anunchai [4 ]
White, George [3 ]
Chopra, Gaurav [3 ,5 ]
Rongnoparut, Pornpimol [1 ]
Samudrala, Ram [3 ]
Tongsima, Sissades [2 ]
机构
[1] Mahidol Univ, Fac Sci, Dept Biochem, Bangkok 10400, Thailand
[2] Genom Inst, Natl Ctr Genet Engn & Biotechnol, Pathum Thani, Thailand
[3] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA
[4] Mahidol Univ, Fac Pharm, Dept Pharmacol, Bangkok 10700, Thailand
[5] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
关键词
HUMAN CYTOCHROME-P450 2C9; MOLECULAR-DYNAMICS; SUBSTRATE-SPECIFICITY; WARFARIN; P4502C9; ALLELE; GENOTYPE; PHARMACOKINETICS; FLURBIPROFEN; RECOGNITION;
D O I
10.1371/journal.pone.0074053
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cytochrome P450 2C9 (CYP2C9) is crucial in excretion of commonly prescribed drugs. However, changes in metabolic activity caused by CYP2C9 polymorphisms inevitably result in adverse drug effects. CYP2C9*2 and *3 are prevalent in Caucasian populations whereas CYP2C9*13 is remarkable in Asian populations. Single amino acid substitutions caused by these mutations are located outside catalytic cavity but affect kinetic activities of mutants compared to wild-type enzyme. To relate distal effects of these mutations and defective drug metabolisms, simulations of CYP2C9 binding to anti-coagulant (S)-warfarin were performed as a system model. Representative (S)-warfarin-bound forms of wild-type and mutants were sorted and assessed through knowledge-based scoring function. Interatomic interactions towards (S)-warfarin were predicted to be less favorable in mutant structures in correlation with larger distance between hydroxylation site of (S)-warfarin and reactive oxyferryl heme than wild-type structure. Using computational approach could delineate complication of CYP polymorphism in management of drug therapy.
引用
收藏
页数:9
相关论文
共 44 条
[1]   The Cambridge Structural Database: a quarter of a million crystal structures and rising [J].
Allen, FH .
ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1) :380-388
[2]   Allele and genotype frequencies of CYP2C9 in a Korean population [J].
Bae, JW ;
Kim, HK ;
Kim, JH ;
Yang, SI ;
Kim, MJ ;
Jang, CG ;
Park, YS ;
Lee, SY .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (04) :418-422
[3]   Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies [J].
Banu, Hussaina ;
Renuka, N. ;
Vasanthakumar, Geetha .
BIOCHIMIE, 2011, 93 (06) :1028-1036
[4]   A generalized knowledge-based discriminatory function for biomolecular interactions [J].
Bernard, Brady ;
Samudrala, Ram .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2009, 76 (01) :115-128
[5]   A graph-theory algorithm for rapid protein side-chain prediction [J].
Canutescu, AA ;
Shelenkov, AA ;
Dunbrack, RL .
PROTEIN SCIENCE, 2003, 12 (09) :2001-2014
[6]  
Case D.A., 2008, AMBER10
[7]   Effects of the CYP2C9*1/*13 Genotype on the Pharmacokinetics of Lornoxicam [J].
Choi, Chang-Ik ;
Kim, Mi-Jeong ;
Jang, Choon-Gon ;
Park, Young-Seo ;
Bae, Jung-Woo ;
Lee, Seok-Yong .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 (06) :476-480
[8]   The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase [J].
Crespi, CL ;
Miller, VP .
PHARMACOGENETICS, 1997, 7 (03) :203-210
[9]   Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin [J].
Gage, B. F. ;
Eby, C. ;
Johnson, J. A. ;
Deych, E. ;
Rieder, M. J. ;
Ridker, P. M. ;
Milligan, P. E. ;
Grice, G. ;
Lenzini, P. ;
Rettie, A. E. ;
Aquilante, C. L. ;
Grosso, L. ;
Marsh, S. ;
Langaee, T. ;
Farnett, L. E. ;
Voora, D. ;
Veenstra, D. L. ;
Glynn, R. J. ;
Barrett, A. ;
McLeod, H. L. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 84 (03) :326-331
[10]  
GOTOH O, 1992, J BIOL CHEM, V267, P83